Ten post jest także dostępny w języku: polski
In December 2020, the pharmaceutical company AstraZeneca announced that it has entered into an agreement to acquire the pharmaceutical company Alexion. The value of the transaction is $39bn. The transaction is to be completed in Q3 2021.
AstraZeneca will take over Alexion for $39 billion
On 12 December 2020, the pharmaceutical company AstraZeneca announced that it has entered into an agreement to purchase a biopharmaceutical company specialised in developing treatments for rare diseases, Alexion. The transaction, which still needs to be approved by the relevant regulatory authorities, is expected to be completed in Q3 2021. The transaction is worth $39bn.
AstraZeneca and Alexion will continue to work on the 11 molecules in Alexion’s pipeline.
Acquisition to strengthen AstraZeneca in immunology
Alexion is a biopharmaceutical company that creates therapies for people suffering from rare diseases. Alexion’s product portfolio includes Soliris (eculizumab), one of the most expensive drugs in the world. In Poland it has been reimbursed since 2018.
The acquisition will allow AstraZenec to increase its presence in the field of immunology.
AstraZeneca is one of the largest pharmaceutical companies in the world and has been present in Poland since 1992 (at that time representative of Astra was established in Poland and at present the company operates in Poland under the name AstraZeneca Pharma Poland). AstraZeneca employs about 82,000 people worldwide, of which over 2,000 in Poland. Its medicines are available in over 100 countries worldwide.